Professionals 234 Users Online

Electrophysiology Ablation Market

The prevalence of Atrial Fibrillation (AF) leading to an increased demand for cardiac arrhythmia therapy will drive the global market for electrophysiology ablation

Electrophysiology Ablation Market Segmented by Ablation Catheters, Diagnostic Catheters, and Access Devices in Supraventricular Tachycardia Ablation, ventricular tachycardia and Atrial Fibrillation

Electrophysiology Ablation Market Outlook (2023-2033)

Worldwide revenue from the electrophysiology ablation market stands at US$ 3.1 Bn in 2022, with the global market estimated to surge ahead at a CAGR of 8.8% to reach a valuation of US$ 7.9 Bn by the end of 2033.

Attributes Key Insights

Electrophysiology Ablation Market Size (2022)

US$ 3.1 Bn

Projected Market Value (2033)

US$ 7.9 Bn

Global Market Growth Rate (2023-2033)

8.8% CAGR

Market Share of Top 5 Countries

52.8%

As assessed by Persistence Market Research, hospital segment is expected to hold a largest market value of US$ 1.9 Bn by 2023 globally. Overall, electrophysiology ablation market sales account for approximately 6.4% revenue share in the global cardiac monitoring devices market, which was valued at around US$ 28.0 Bn at the end of 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of the Global Electrophysiology Ablation Market from 2013 to 2022 Vs Market Outlook for 2023 to 2033

The global market for electrophysiology ablation recorded a historic CAGR of 8.5% in the last 9 years from 2013 to 2022.

The prevalence of Atrial Fibrillation (AF) is increasing, and electrophysiological ablation treatments are becoming more widely used, which has increased the demand for cardiac arrhythmia therapy. Technological improvements in electrophysiology and related cardiac monitoring devices like the electroencephalography (EEG) device are facilitated by the introduction of new electrophysiology ablation variants.

Atrial fibrillation prevalence is rising globally, driving up demand for cardiac ablation procedures and electrophysiology devices. The changing lifestyles of individuals, which significantly raise the risk for atrial fibrillation occurrences including high blood pressure, attack, cardiac arrest, and others, are one of the main causes of this rise in demand.

  • For instance, the global burden of atrial fibrillation was about 59.7 million in 2019, according to data from the British Cardiovascular Society. By 2030, the Centers for Disease Control & Prevention (CDC) predicts that there will be about 12.1 million cases of atrial fibrillation (AFib) in the U.S. alone.

Electrophysiology ablation device manufacturers can benefit from profitable potential for significant revenue development as a result of growing demand for cost-effective diagnostic options and increasing public awareness of electrophysiology ablation.

The global market is thus likely to show high growth over the coming years at a CAGR of 8.8% and reach a global market size of US$ 7.9 Bn by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What Factors Will Drive the Electrophysiology Ablation Market to Grow Over Forecast Period?

Electrophysiology Ablation is Now Considered to Be the First Line of Treatment for Arrhythmias”

In the past, doctors would advise using medicines to prevent arrhythmias from being diagnosed. Antiarrhythmic medication at the prescribed dosage was made available to control the abnormal heart condition. Currently, there are various antiarrhythmic medications on the market for AF and other related arrhythmias, some of which are produced by large pharmaceutical companies. Due to the development of precise ablation methods, the usage pattern for antiarrhythmic drugs underwent a change that significantly affected sales, which in turn had an impact on the market's overall revenue.

  • Dronedarone, a novel antiarrhythmic medication from Sanofi-Aventis, was banned due to an increase in creatinine concentration, which reportedly caused some serious adverse effects more frequently in the dronedarone group. Dronedarone was initially prescribed for patients with atrial fibrillation and reduced left ventricular systolic function.

The growth of electrophysiological ablation treatments is due to the fact that antiarrhythmic drugs are no longer the first line of treatment for the majority of AF surgeries. Adoption of such techniques would lead to an increase in treatment facilities, which would raise the need for ablation-related products like catheters.

Multiple use of conventional catheter”

Catheters used in electrophysiological cases are often single-use products. Reusable products cannot be used in electrophysiological operations because of a number of issues. Companies frequently adopt this style and have created catheters as a consumable product. The main cardiac care companies are thought to control the market for electrophysiological ablation. However, as new players enter the market, it is possible to anticipate products that will significantly change the product category.

  • The labels used today to describe catheters have been redefined by CathRx's newly released device. A brand-new, innovative line of electrophysiology catheters with the name Khelix was developed and manufactured by CathRx. The company's extensive and continually expanding patent portfolio served as the foundation for the creation of the product line, which is thought to be unique and is the first generation of "reusable" diagnostic and therapeutic catheters for the treatment of cardiac arrhythmias.

The technology enables it to be utilized in routine electrophysiological practice about 20 times. The product type under consideration adds value to the electrophysiological ablation product type.

Technological Advancements”

To meet the desire for less intrusive, safer, and more affordable cardiac arrhythmia detection and therapy, electrophysiological equipment have been upgraded with a number of smart technologies and features. In order to address the issues of lockdown and social isolation brought on by the pandemic, the improved technologies of advanced cardiovascular imaging and telerobotics, wireless and real-time monitoring, are shaping the future of the electrophysiological devices, therapies, and procedures.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Is there Any Impact on the Growth of the Global Electrophysiology Ablation Market?

“Product recalls affecting the overall market adoption/pattern

Recalled products have an impact on the market as a whole, and manufacturers are most likely to suffer as they could have an indirect or direct effect on their company. Product recalls cause a disruption in net sales. Aside from that, other market leaders or participants fill the gap left by recalled products. Due to a few problems, the FDA issued a Class 3 recall for Biosense Webster's Duo-Decapolar EP catheter in 2011. The company's sales suffered for the following several months as a result of this nationwide recall. While everything was going on, St. Jude Medical profited from the circumstance and seize the chance by presenting customers with alluring offers on their selection of goods.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the U.S. Electrophysiology Ablation Market Booming?

“Advanced Healthcare Infrastructure”

The U.S. is expected to hold around 21.9% market share in the global electrophysiology ablation market at the end of 2023.

The development of infrastructure for cardiovascular treatment, public and private investments in the healthcare industry, and improved acceptance and use of new technology all contribute to the U.S.'s high revenue generation. Furthermore, a favourable reimbursement system and increased public awareness of cardiac health will present profitable prospects for companies who manufacture electrophysiological ablation equipment.

Will the Germany Be a Lucrative Market for the Manufacturers?

“Rising Demand for Ablation Therapies”

With a 5.3% market share, Germany will hold a fair amount of share in global market at the end of 2023.

The need for electrophysiology ablation procedures is rising in Germany due to a number of factors, including an ageing population, the presence of several ablation clinics, a rise in the popularity of minimally invasive cardiac procedures, and an efficient healthcare system. Additionally, throughout the projection period, demand is anticipated to be driven by rising awareness of the advantages of ablation therapies over conventional medicinal and surgical methods.

How is Japan Emerging as a Prominent Market for Electrophysiology Ablation?

“Market Penetration by Major Players”

Japan is estimated to hold market share of about 11.7% of the global electrophysiology ablation market in 2023.

The market in Japan is expanding as a result of a number of factors, including a large patient population, growing government support for expanding public access to advanced therapeutic and surgical procedures, and strengthening national healthcare infrastructure with the entry of major international players.

Category-wise Insights

Which Product Segment is Driving Growth of the Global Electrophysiology Ablation Market?

Demand for Ablation Catheter to continue gaining Traction”

Ablation catheters segment is expected to hold highest share of around 47.0% of the product segment by the end of 2023.

The majority of arrhythmias can be treated safely and effectively with this product, with cure rates of 80–90%. The product has the power to enhance quality of life and prevent arrhythmia symptoms including fatigue, weakness, and shortness of breath. Ablation catheters are the most profitable and widely used device on the market because of their life-saving benefits.

Which Application is Expected to Dominate the Global Market?

“One of the Major Cause of Deaths Among Cardiovascular Disorders”

Atrial fibrillation (AF) segment is expected to hold the larger share of about 52.9% by the end of 2023.

The main reason fuelling segment expansion is an increase in atrial fibrillation patients. AFib, for instance, is the leading diagnosis in almost 454,000 hospital admissions in the United States each year, according to data from the CDC, and it also plays a major role in more than 150,000 deaths. Atrial fibrillation was listed as the primary cause of death in more than 183,321 deaths in 2019.

Which End User is Expected to Emerge as a Market Leader in the Future?

“Increasing Number of Office Settings Worldwide”

Hospitals segment is expected to hold the larger share globally and reach a market valuation of US$ 1.9 Bn by 2023.

Since more walk-in patients are getting electrophysiological ablation procedures, there are more qualified medical professionals available, and interventional cardiologists are using more advanced equipment and gadgets in hospitals. This market is also being driven by the growing inclination of a sizable patient pool to have ablation surgery in ambulatory service facilities.

Competition Landscape

Heart rhythm therapy has made significant advancements and innovations during the last few years. The ecosystem for future product advancements in the electrophysiological ablation industry will be shaped by the ongoing research. Market leaders are working on maintaining their dominance in the premium sector. Market leaders are concentrating on increasing their product portfolio to increase their customer insight skills globally as the overall market for catheters is consolidating.

Key instances include:

  • In Sep 2021, Medtronic plc collaborated with Mpirik in order to address care disparities related to preventing Sudden Cardiac Arrest (SCA), a disease in which the heart unexpectedly and suddenly heart stops.
  • In Jan 2022, Affera, Inc., which provides treatments for cardiac arrhythmias, entered into an agreement to be acquired by Medtronic plc. By acquiring this company, Medtronic hoped to enhance its electrophysiology by diversifying into new EP markets like mapping and navigation.

Electrophysiology Ablation Industry Report Scope

Attribute Details

Forecast Period

2023-2033

Historical Data Available for

2013-2022

Market Analysis

USD Million for Value

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • BENELUX
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • GCC
  • North Africa
  • South Africa

Key Market Segments Covered

  • Product
  • Application
  • End User
  • Region

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Key Companies’ Profile

  • Biosense Webster
  • Abbott Laboratories
  • MEDTRONIC PLC
  • Boston Scientific Corporation
  • CathRx Ltd
  • Biotronik SE & Co. KG.
  • Japan Lifeline Co
  • ATRICURE, INC.
  • Auris Health
  • Biomerics

Customization & Pricing

Available upon Request

Key Segments Covered in Electrophysiology Ablation Industry Research

Product:

  • Diagnostic Catheter
  • Ablation Catheter
  • Access Device

Application:

  • Supraventricular tachycardia (SVT) ablation
  • Ventricular tachycardia(VT/VPC)
  • Atrial fibrillation (AF)

End User:

  • Hospital
  • Ambulatory Surgical Centre
  • Clinic

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Abbott
  • Boston Scientific
  • Biosense Webster (Johnson&Johnson)
  • MEDTRONIC PLC
  • CathRx Ltd
  • Biotronik SE & Co. KG.
  • Japan Lifeline Co
  • ATRICURE,
  • Auris Health
  • Biomerics

- Frequently Asked Questions -

The global market is currently valued around US$ 3.1 Bn in 2022.

Sales of the market are set to witness growth at a CAGR of 8.8% and be valued at around US$ 7.9 Bn by 2033.

Demand for the market increased at an 8.5% CAGR from 2013 to 2022.

U.S., Canada, UK, Japan and India accounted for the major share in the global market as of year 2022, holding around 52.8% market share.

The U.S. is expected to account for around 21.9% share of the global market in 2023.

Latin America will account for around 7.8% share of the global market in 2023.

Japan market is expected to hold a share of about 11.7% in the global electrophysiology ablation market in 2023.

Germany is expected to hold about 5.3% of the global market share at the end of 2023.

UK is expected to grow over a CAGR of 8.7% over the forecast duration.

India is expected to grow over a CAGR of 9.7% over the forecast duration.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate